Featured
Is neuromodulation the breakthrough that Alzheimer's has been waiting for?
Sinaptica's precision neuromodulation combines TMS and EEG to target memory networks, offering new hope in Alzheimer's care.
Is neuromodulation the breakthrough that Alzheimer's has been waiting for?
Sinaptica's precision neuromodulation combines TMS and EEG to target memory networks, offering new hope in Alzheimer's care.
Mayo Clinic-backed, Halle Berry-approved: Pendulum’s Dr. Colleen Cutcliffe is tackling type 2 diabetes before it even starts.
As clinical trials progress, Pendulum hopes their medical evidence can beat the status quo and encourage Americans to take preventative care into their own hands.
From paper to pancreas: how Aspect Biosystems is leading a bioprinting revolution
A recent multi-billion dollar deal with Novo Nordisk in diabetes and obesity, and an injection of significant funding through a $200 million government partnership - Aspect is worth watching as they enter 2025.
Could a single pill crack the code of treating Alzheimer's disease?
By targeting toxic protein clumps in the brain, Dr. Martin Tolar, founder-CEO of Alzheon, aims to outsmart Alzheimer’s decades ahead of symptoms - and reshape global neurology.
What are GLP-1 agonists and how valuable are they?
GLP-1 is quickly becoming one of the most famous hormones in the world.
Under The Microscope: The Basics of Cell and Gene Therapy
Genomics is seeing its golden age in the clinic. How did we get here?
Wearable diagnostics: Continuous Glucose Monitoring Devices
How do they work, and how big is the market?
Announcing Vital Signs in Fortune
We will publish our in-depth healthcare report, Vital Signs, in Fortune magazine on December 1, 2024. Vital Signs: Future of Healthcare will appear in Fortune ahead of one of the most important events in the industry: JPM Week, the annual healthcare conference hosted by J.P. Morgan at the Westin
The 3 Biggest Biotech Events in 2025
We expect the attendance for each to be well over 20,000 in 2025.